Msohsp.wildapricot.org



Maine Society of Health-System PharmacistFall MeetingNovember 2, 2019Pharmacist HandoutImpact of Clinician Burnout on Patient Safety: Journey to a Resilient & Thriving Healthcare WorkforcePaul W. Abramowitz, PharmD, Sc.D (Hon), FASHP, ASHP’s CEO0837-9999-19-255-L05-PDefine burnout, well-being, and resilienceExplain why clinician burnout is a patient care and healthcare workforce problemDiscuss the U.S. National Academy of Medicine Clinician Well-Being and Resilience Action CollaborativeIdentify strategies to improve well-being and resilience in the healthcare workforceVancomycin AUC: It’s Easy as 1,2,3Brian McCullough, PharmD, BCPS0837-9999-19-259-L01-PDescribe vancomycin’s pharmacodynamics activityIdentify the current recommendations for vancomycin dosingRecognize the proper calculation for area under the curvePreventing Harm and Reducing Maine Overdose Deaths: A Naloxone and SUD Stigma Primer for PharmacistsStephaine Nichols, PharmD, BCPS, BCPP, FCCPKenneth McCall, BSPharm, PharmD, BCGP, FAPhA0837-9999-19-261-L01-PRecognize the impact of the opioid epidemic in MaineIdentify stigmatizing terms related to patients with substance use disorder (SUD) and select appropriate alternativesRecognize the impact of stigmatizing terminology on patient careRecognize non-stigmatizing language to a scenario involving a patient with SUDReview SUD to other medical/psychiatric diseases and describe the harm reduction approach to careDescribe the mechanism of naloxone and its place in therapyIdentify persons at risk of an opioid overdose and signs of an overdoseSummarize the characteristics of the various naloxone formulations including administration techniquesDiscuss critical patient education points regarding opioid overdose and naloxoneBiosimilars: Current Trends and Future DirectionsChristopher Peric, PharmD, BCPS0837-9999-19-257-L01-PReview biosimilar regulatory and development pathwaysDescribe current formulary management approaches for biosimilarsDiscuss clinical and financial considerations for future biosimilar useDelegate Update on ASHP’s Summer MeetingKathryn Sawicki, PharmDMatthew Christie, PharmD0837-9999-19-264-L04-PReview the policies presented for change at ASHP’s summer meetingAssess policies and changes that were extensively discussedExplain the use of policies in the national law making processIdentify policies up for future discussion ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download